C ase presentation:
A 75-year-old woman was referred to cardiology for optimization of cardiovascular risk factors before starting a new cancer treatment. She was diagnosed with IgG-κ multiple myeloma (MM) 2 years previously that progressed after her previous treatments. Her medical history also included type 2 diabetes mellitus, hypertension, and a remote history of deep vein thrombosis treated with a "blood thinner" for 6 months. Her hematologist has determined that a combination of carfilzomib, lenalidomide, and dexamethasone is the best treatment option for this patient but is concerned about the risk of cardiovascular complications from the new treatment and wants the patient to undergo evaluation by a cardiologist.
Overview
MM is a plasma cell malignancy characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction. 1 MM accounts for 1% of all cancers and ≈13% of all hematologic malignancies. Approximately 86 000 new cases of MM occur annually worldwide and affect primarily older individuals with a median age of diagnosis of ≈70 years. 2 Over the past few decades, overall survival has improved from an age-adjusted 5- Figure 1 shows the milestones in MM treatment.
Thrombosis and MM
Cancer is associated with increased risk of venous thromboembolic events (VTEs). 4 As early as 1868, Trousseau 5 described the relationship between malignancy and venous thrombosis. A large case-control study has shown that malignancy by itself increases the risk of VTEs by 7-to 10-fold; hematologic malignancies, including MM, are especially associated with high VTE risk (up to 28-fold), representing the highest reported risk of VTEs among patients with cancer. 6 A hypercoagulable state in MM was recognized in the early 1970s, and MM was described as an independent risk factor for VTEs. 7, 8 Before the introduction of IMiD therapy, ≈10% of patients with MM treated with chemotherapy experienced VTE complications, and the median time from diagnosis to the development of VTEs was 8.5 months. 9 VTEs have increasingly been observed in patients with MM treated with IMiDs, especially when used in combination with highdose dexamethasone or chemotherapy. 
Increased VTE Risk With IMiDs
The increased VTE risk associated with IMiDs came to attention in 2001, when 2 separate phase 2 clinical trials using thalidomide-based chemotherapy reported a high incidence of VTEs: 7% and 27%. 11 The increased risk of VTEs was again observed in later thalidomide trials and led to a protocol amendment that thromboprophylaxis would be initiated for patients receiving thalidomide-based regimens. Patients receiving dexamethasone, which was commonly given in combination with thalidomide, were at particularly high risk for VTEs. A meta-analysis of >3000 patients with MM showed that thalidomide increased the VTE risk by 2.6 times; when thalidomide was combined with dexamethasone, the VTE risk was increased by 8-fold.
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Lenalidomide and pomalidomide, potent derivatives of thalidomide, have also demonstrated increased propensity for VTEs. The incidence of VTEs associated with these agents was lower in trials with mandatory thromboprophylaxis (Table) .
Increased Arterial Thromboembolic Risk in MM
Patients with MM also have a higher risk of arterial thromboembolic events (ATEs), including coronary artery disease and cerebrovascular disease. Increased risk might be due partially to a high burden of cardiovascular comorbidities in the older patient population. However, a prospective cohort study of younger patients with MM (age, 18-65 years) reported a high incidence of ATEs (5.6%), with a median age of onset of 59 years. Hypertension and smoking were significantly associated with ATEs, with a relative risk of 11.7 and 15.2, respectively. Thalidomide treatment was not associated with increased ATE risk in this prospective cohort. 13 On the contrary, increased ATE risks have been observed with lenalidomide treatment. In the long-term follow-up of 704 patients with MM in 2 phase 3, randomized, clinical trials, the incidences of myocardial infarction and cerebrovascular events were 1.98% and 3.4%, respectively, in patients treated with lenalidomide and dexamethasone compared with 0.57% and 1.7%, respectively, in patients treated with dexamethasone alone. 14 Therefore, lenalidomide carries a black box warning of significant myocardial Figure 2 . Mechanisms of increased venous thromboembolic events (VTEs) in multiple myeloma (MM). Several mechanisms involving complex pathways are implicated in the increased VTE risk in patients with MM. Monoclonal proteins secreted by myeloma cells can cause hyperviscosity, can increase the amount of fibrin protofibrils, and are associated with lupus anticoagulant and protein C and S deficiencies. Bone marrow stromal cells secrete many inflammatory cytokines. Immunomodulatory drug (IMiD) treatment, especially when combined with dexamethasone and other chemotherapies, further potentiates the production of cytokines, which mediate interactions among myeloma cells, bone marrow stromal cells, and endothelial cells, with resultant elevation of factor VIII, von Willebrand factor, fibrinogen, and D-dimer levels. IMiD treatment is also associated with acquired activated protein C resistance. All of these factors contribute to endothelial cell dysfunction, platelet activation, and thrombosis formation. The concomitant use of dexamethasone, other chemotherapeutic agents, and erythropoietin (EPO) has been shown to increase VTE risk. Combining bortezomib with IMiDs reduces VTE risk, indicating a possible thromboprotective role of bortezomib. On the contrary, carfilzomib has been shown to increase VTE risk in clinical trials. IL-1β indicates interleukin-1β; IL-6, interleukin 6; TNF-α, tumor necrosis factor-α; and VEGF, vascular endothelial growth factor. 
Thromboprophylaxis
As a result of the increasing use of IMiD-based treatment regimens, the prevention of VTEs has become an important consideration during MM treatment. Aspirin (81-325 mg daily), low-molecular-weight heparin, fixed low-dose warfarin (1-1.25 mg daily), and full-dose warfarin (target international normalized ratio, 2-3) have all been used for prophylaxis of VTEs. Fixed low-dose warfarin has generally been shown to be ineffective and is no longer used. 16 Currently, there are no guidelines on the optimal thromboprophylactic regimen. The specific form of thromboprophylaxis recommended for a given patient is ultimately based on the treating physician's best clinical judgment 17 and on the patient's individual risk factors, disease status, and treatment regimens. The International Myeloma Working Group has made an effort to create recommendations on VTE risk assessment and thromboprophylaxis. However, given the limitations of available data, these recommendations were based mainly on expert opinions; therefore, they should not be considered firm guidelines. 16, 17 IMiD indicates immunomodulatory agents; and VTE, venous thromboembolic events.
*Aspirin (81-325 mg daily), low-molecular-weight heparin, fixed lowdose warfarin (1-1.25 mg daily), and full-dose warfarin (target international normalized ratio, 2-3) have all been used for prophylaxis. Choice of thromboprophylaxis was based largely on physicians' discretion.
†Thalidomide and lenalidomide were used in combination with other therapeutic agents, including melphalan, doxorubicin, and cyclophosphamide. 
Individual Risk Factors

Recommendations
• Aspirin 81-325mg once daily should only be recommended for low-risk patients (≤ 1 individual or myeloma-related risk factor) • LMWH (equivalent of enoxaparin 40mg once daily) or full-dose warfarin (target INR 2-3) should be recommended in the presence of ≥ 2 individual or myeloma-related risk factors • LMWH or full-dose warfarin should be considered in all patients who receive high-dose dexamethasone or doxorubicin or multiagent chemotherapy, independent of the presence of additional risk factors • The dose of LMWH should be adjusted according to renal function. LMWH is generally not recommended for patients with creatinine clearance < 30ml/minute • Thromboprophylaxis should be provided for the first 4 to 6 months of treatment, until disease control is achieved or as long as the risk of VTE remains high In patients with cancer, the majority of VTEs appear within 12 months from diagnosis. In MM, most VTEs have been reported in the first 6 months of treatment, and all episodes occurred within the first 12 months. Therefore, it is recommended that thromboprophylaxis be provided for the first 4 to 6 months; longer periods should be considered in the presence of additional risk factors. 17 INR indicates international normalized ratio; and LMWH, low-molecular-weight heparin. The American College of Chest Physicians guidelines recommend lowmolecular-weight heparin or low-dose unfractionated heparin in outpatients with tumors and risk factors for VTEs, including thalidomide and lenalidomide therapy (Grade 2B recommendation 18 ; Figure 3 ).
Questions About PIs and Risk of Thrombosis
PIs are a cornerstone in MM management and have contributed substantially to the improvement in survival. Currently, 2 PIs, bortezomib and carfilzomib, are approved for MM treatment. Bortezomib, the first in class, was first approved in 2003, whereas carfilzomib was approved in 2012.
PIs are frequently used with IMiDbased regimens. Bortezomib, either alone or in combination, does not appear to result in an increased VTE risk, with low rates of 0% to 5%. 19 A comprehensive review of the available data on phase 3 studies indicated that bortezomib has a protective effect against elevated VTE risk in combination with regimens of thrombogenic potential, including IMiDs. 19 Another clinical study in which the risk of VTEs was 1.38 times higher in patients treated with thalidomide without bortezomib also suggests a possible protective role of bortezomib against VTEs. 20 The clinically observed thromboprotective effect of bortezomib was supported by mechanistic studies in which bortezomib enhanced endothelial thrombomodulin expression via Krüppel-like transcription factors. 21, 22 Early clinical trials with carfilzomib involved patients with MM who had been heavily pretreated and had advanced disease and in whom carfilzomib was used as single therapy. In this setting, carfilzomib, although effective for cancer therapy, showed significant cardiotoxicity. In an integrated safety analysis of all pivotal phase 2 trials in which carfilzomib was used as monotherapy in patients with MM who failed previous treatments, 22.1% had cardiotoxicity, which included cardiac arrhythmia (13.3%), heart failure (7.2%), and cardiovascular-related deaths (1.5%). 23 Results from a recently published, randomized phase 3 trial (ASPIRE trial) comparing the efficacy of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone showed a higher incidence of heart failure (6.4% versus 4.1%), ischemic heart disease (5.9% versus 4.6%), VTEs (10.2% versus 6.2%), and hypertension (14.3% versus 6.9%) in the carfilzomib arm. 24 The addition of carfilzomib was more effective for MM treatment in this study, although the safety data suggested a heterogeneous pattern of cardiovascular toxicities associated with carfilzomib, with a greater presence of vascular toxicities than typical myocardial toxicity seen with other therapies such as anthracyclines. Undoubtedly, more data about the cardiovascular safety of carfilzomib, especially in the front-line setting, will emerge from upcoming studies. However, the results of ASPIRE pointed to a concerning thrombotic risk when carfilzomib is combined with lenalidomide. Cardiologists need to be aware of these toxicities and work closely with patients and their oncology teams to provide optimal cardiovascular care during MM treatment.
Case Conclusion
The patient was seen and followed up by a cardio-oncologist (cardiologist who focuses on cardiovascular care of cancer patients). The patient's hypertension and diabetes mellitus increased her risk of cardiovascular toxicities, and an aggressive effort was made to control these risk factors by optimizing her hypertension and diabetes regimens. A baseline echocardiogram showed normal ejection fraction and no regional wall motion abnormalities. Laboratory results showed a creatinine clearance of 50 mL/min. Additionally, given her history of a deep vein thrombosis and other cardiovascular comorbidities, the patient was considered at high risk of developing VTEs on her combination therapy, which included carfilzomib, lenalidomide, and dexamethasone.
She was prescribed enoxaparin 40 mg injected subcutaneously daily as thromboprophylaxis. She was followed up closely in the cardiology clinic, and her hypertension and diabetes mellitus were well controlled. At the 6-month follow-up, the patient had responded well to her MM therapy and had not suffered any cardiovascular events, including VTEs.
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